Edwards Lifesciences Corp (EW) Shares Sold by Braun Bostich & Associates Inc.

Braun Bostich & Associates Inc. cut its stake in Edwards Lifesciences Corp (NYSE:EW) by 18.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,029 shares of the medical research company’s stock after selling 684 shares during the period. Braun Bostich & Associates Inc.’s holdings in Edwards Lifesciences were worth $580,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Acadian Asset Management LLC lifted its holdings in shares of Edwards Lifesciences by 167.3% during the first quarter. Acadian Asset Management LLC now owns 2,470 shares of the medical research company’s stock valued at $473,000 after purchasing an additional 1,546 shares during the last quarter. Wetherby Asset Management Inc. lifted its holdings in shares of Edwards Lifesciences by 11.5% during the first quarter. Wetherby Asset Management Inc. now owns 3,273 shares of the medical research company’s stock valued at $626,000 after purchasing an additional 337 shares during the last quarter. Checchi Capital Advisers LLC lifted its holdings in shares of Edwards Lifesciences by 9.5% during the first quarter. Checchi Capital Advisers LLC now owns 2,218 shares of the medical research company’s stock valued at $424,000 after purchasing an additional 193 shares during the last quarter. Rational Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 9,660.3% during the first quarter. Rational Advisors LLC now owns 12,786 shares of the medical research company’s stock valued at $2,447,000 after purchasing an additional 12,655 shares during the last quarter. Finally, Piedmont Investment Advisors Inc. lifted its holdings in shares of Edwards Lifesciences by 1.5% during the first quarter. Piedmont Investment Advisors Inc. now owns 18,565 shares of the medical research company’s stock valued at $3,552,000 after purchasing an additional 273 shares during the last quarter. Institutional investors and hedge funds own 83.53% of the company’s stock.

In other news, VP Catherine M. Szyman sold 1,146 shares of the business’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $179.10, for a total value of $205,248.60. Following the sale, the vice president now directly owns 22,229 shares in the company, valued at approximately $3,981,213.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael A. Mussallem sold 32,800 shares of the business’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $167.89, for a total transaction of $5,506,792.00. Following the completion of the sale, the chief executive officer now owns 67,126 shares in the company, valued at $11,269,784.14. The disclosure for this sale can be found here. In the last quarter, insiders sold 152,306 shares of company stock worth $26,869,558. Corporate insiders own 1.63% of the company’s stock.

Shares of EW opened at $169.97 on Friday. The company has a market cap of $35.86 billion, a P/E ratio of 36.16, a PEG ratio of 2.20 and a beta of 0.85. The company has a quick ratio of 2.69, a current ratio of 3.66 and a debt-to-equity ratio of 0.19. Edwards Lifesciences Corp has a twelve month low of $134.38 and a twelve month high of $197.86.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.23 by $0.09. The business had revenue of $993.00 million for the quarter, compared to analysts’ expectations of $989.87 million. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. The company’s revenue was up 11.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.22 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Corp will post 5.28 EPS for the current fiscal year.

Several equities analysts have recently issued reports on EW shares. Stifel Nicolaus reiterated a “buy” rating and set a $190.00 target price on shares of Edwards Lifesciences in a report on Sunday, February 3rd. Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a report on Monday, February 4th. Citigroup lifted their target price on shares of Edwards Lifesciences from $119.00 to $130.00 and gave the company a “sell” rating in a report on Monday, February 25th. UBS Group lifted their target price on shares of Edwards Lifesciences from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Tuesday, March 12th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $215.00 target price (up from $190.00) on shares of Edwards Lifesciences in a report on Monday, March 18th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $187.00.

WARNING: “Edwards Lifesciences Corp (EW) Shares Sold by Braun Bostich & Associates Inc.” was originally reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/24/edwards-lifesciences-corp-ew-shares-sold-by-braun-bostich-associates-inc.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Story: How does new data get added to a blockchain?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.